Novo Nordisk A/S
East and Gulf Coast ports strike, with ILA longshoremen walking off job from New England to Texas, stranding billions in trade
Shipping containers sit stacked in the Port of Newark on September 30, 2024 seen from New York City. A massive strike shutting down ports across the East and Gulf coasts began at midnight as members of the International Longshoremen’s Association continue to make salary and other demands to the United States Maritime Alliance, which controls […]
Read More
Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more
Check out the companies making headlines in midday trading: Bristol-Myers Squibb — The drug maker jumped more than 3% after the U.S. Food and Drug Administration approved a highly anticipated schizophrenia drug , the first novel type of treatment for the chronic mental disorder in more than seven decades. Bristol-Myers Squibb expects the twice-daily pill, […]
Read More
Stocks making the biggest moves premarket: Bristol-Myers Squibb, Costco, Super Micro Computer and more
Check out the companies making headlines in premarket trading: Bristol-Myers Squibb — The biopharmaceutical stock jumped 5.3% after the U.S. Food and Drug Administration approved Cobenfy as a treatment of schizophrenia for adults. It marks the first new type of treatment for the mental disorder in several decades. Novo Nordisk — U.S.-listed shares of the […]
Read More
Novo Nordisk’s diabetes drug Ozempic may lower the risk of opioid overdoses, study says
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Novo Nordisk‘s blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study […]
Read More
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good afternoon! Wegovy, […]
Read More
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022. Christopher Goodney | Bloomberg | Getty Images Novo Nordisk‘s top executive is slated to face a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand […]
Read More
Why Eli Lilly and Palo Alto Networks are both up on news from their competitors
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The Dow and S & P 500 were lower Friday after surging to record highs Thursday in response to the Fed cutting interest rates by […]
Read More
Stocks making the biggest moves midday: FedEx, Nike, Constellation Energy and more
Check out the companies making headlines in midday trading: FedEx — The delivery giant plunged more than 13% after reporting a steep quarterly earnings drop. The company also lowered its full-year revenue forecast. CEO Raj Subramaniam said industrial demand was softer than expected, while FedEx’s customers continued to shift to cheaper, slower delivery options, which […]
Read More
FTC sues drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen use practices that boost their profits while “artificially” inflating costs for patients. The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts. All are […]
Read More
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]
Read More